ANAB241220C15000
- 0.00
- 0.000.00%
AnaptysBio Newsroom
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating
AnaptysBio Price Target Cut to $66.00/Share From $75.00 by JP Morgan
AnaptysBio Is Maintained at Overweight by JP Morgan
AnaptysBio Analyst Ratings
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $66
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $59
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $56
AnaptysBio Analyst Ratings
HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $45 to $80
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
AnaptysBio: Promising Pipeline and Strong Cash Reserves Underscore Buy Rating Despite Recent Stock Decline
Promising Pipeline Developments Position AnaptysBio as a Buy: Focus on ANB032 and Rosnilimab
BTIG Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $45